A Phase 4 interventional study of Polyethylene glycol 3350 and Placebo, maltodextrin 500 powder for solution in Constipation, sponsored by Bayer. Completed. Open to participants aged 17 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing polyethylene glycol 3350 in Constipation — 3 open to participants now, 4 under way, none of them phase 3. polyethylene glycol 3350 · Constipation.
Among the 27 studies testing polyethylene glycol 3350 in Constipation, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 16 in phase 4, and was the 11th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 27 studies testing polyethylene glycol 3350 in Constipation are open now, in 2 countries. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 2–18 · Healthy volunteers
Chad R. Tracy · Sites in United States
Ages 30–100 · Healthy volunteers
Shaare Zedek Medical Center · Sites in Israel
Ages 4–17
By country, each count listing its studies:
polyethylene glycol 3350: first FDA approval 1984 (GOLYTELY). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 17 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 203 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 100 across the 27 interventional studies. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 27 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 6 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing polyethylene glycol 3350 in Constipation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05821309Indiana UniversityEvaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen | 2027-07 |
| NCT07604025Shaare Zedek Medical CenterSenna vs. Polyethylene Glycol 3350 for the Treatment of Retentive Encopresis in Children | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing polyethylene glycol 3350 in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took one of study treatments up to 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MiraLAX® (polyethylene glycol 3350 powder for solution)
Drug: Polyethylene glycol 3350
MALTRIN 500® M500 (maltodextrin 500)
Other: Placebo, maltodextrin 500 powder for solution
Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
Also known as: MiraLAX®
Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
Also known as: MALTRIN® 500 powder for solution
Number of Participants With a Complete Resolution at the Final Visit
A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.
Time frame: 24 hours to 3 days after last dose of seven day treatment period.
| Milestone | Polyethylene Glycol 3350 Powder for Solution | Placebo |
|---|---|---|
| Started | 102 | 101 |
| Completed | 98 | 94 |
| Not completed | 4 | 7 |
| Withdrew: Other | 4 | 6 |
| Withdrew: Non-compliance | 0 | 1 |
A resolution was recorded if the participant has no occurrence of two or more consecutive unsuccessful bowel movements for the rest of the study following the first successful bowel movement.
| Participants | Polyethylene Glycol 3350 Powder for Solution | Placebo |
|---|---|---|
| Number of Participants With a Complete Resolution at the Final Visit | 36 | 23 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Polyethylene Glycol 3350 Powder for Solution | — | 0/102 (0%) | 11/102 (10.8%) |
| Placebo | — | 0/101 (0%) | 11/101 (10.9%) |
| Event | Polyethylene Glycol 3350 Powder for Solution | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 11/102 | 11/101 |
| Age, Continuous(years) | Polyethylene Glycol 3350 Powder for Solution | Placebo | Total |
|---|---|---|---|
| Mean | 45.8 ± 12.52 | 45.0 ± 14.15 | 45.4 ± 13.33 |
| Sex: Female, Male(Participants) | Polyethylene Glycol 3350 Powder for Solution | Placebo | Total |
|---|---|---|---|
| Female | 77 | 68 | 145 |
| Male | 25 | 33 | 58 |
No study locations are listed for this record.
The record gives a start of Nov 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Polyethylene glycol 3350